Growth hormone deficiency (GHD) is the most common hormone deficit in hypopituitarism. GHD not only causes obesity \[[@B1]\], glucose intolerance \[[@B2]\], and dyslipidemia \[[@B3]\] but also decreases aerobic exercise ability \[[@B4], [@B5]\], as a result of restricted oxygen delivery capacity \[[@B6]\]. A current method of diagnosis for GHD depends on multiple GH stimulation tests, such as by insulin and glucagon \[[@B7]\], and these tests place a burden on patients in terms of economy and time. Therefore, an easier and more effective biomarker of GHD has been desired.

Previous studies showed that (pro)renin receptor \[(P)RR\] contributes to tissue renin-angiotensin system-related pathogenesis, such as hypertension and diabetes \[[@B8]\]. Furthermore, there is a report that (P)RR is expressed in pituitary adenoma cells and regulates secretion of GH \[[@B11]\]. In addition, a recent study demonstrated an important role of (P)RR under hypoxic condition \[[@B12]\], in which (P)RR binds to pyruvate dehydrogenase (PDH) protein and maintains the PDH activity through inhibition of its degradation. In fact, it has been reported that serum concentration of the *N*-terminal domain of (P)RR, called the soluble form of (P)RR \[s(P)RR\], is elevated in various hypoxic conditions, such as hypertension \[[@B13]\], sleep apnea syndrome \[[@B14]\], and chronic heart failure \[[@B15]\]. Furthermore, hypoxia in adipose tissue (AT) of obese mice \[[@B16]\] and increased expression of (P)RR in AT of obese mice have also been reported \[[@B20]\].

This study was designed to evaluate if the serum s(P)RR level is elevated in GHD and if so, to assess the origin of s(P)RR and determine the significance of elevated s(P)RR concentration in GHD.

1. Subjects and Methods {#s6}
=======================

A. Study Participants {#s7}
---------------------

In this prospective observational study, 72 adult patients with pituitary or hypothalamic diseases at Tokyo Women's Medical University Hospital were enrolled between December 2011 and December 2013. The study protocol was approved by the Ethics Committee of Tokyo Women's Medical University (2303-R5) and registered in the University Hospital Medical Information Network Clinical Trial Registry (UMIN000006222) on 1 October 2011, and all patients provided written, informed consent. Medical records were used to obtain patient characteristics (such as age, sex, body weight, and history of hypertension) and metabolic parameters (such as creatinine). All patients with hypopituitarism or diabetes insipidus received appropriate supplementation of hydrocortisone, levothyroxine, gonadal steroids, and/or desmopressin. Obesity was defined as body mass index (BMI) of higher than 25 kg/m^2^, according to the criteria by the Japan Society for Study of Obesity \[[@B21]\]. All patients underwent the GH-releasing peptide 2 (GHRP-2) test to diagnose adult severe GHD (SGHD), defined as peak GH concentration \<9 ng/mL \[[@B22]\]. A GH cutoff value of 9 ng/mL with GHRP-2 corresponded to a GH value of 1.8 ng/mL with the insulin tolerance test when the GH value was calibrated with recombinant World Health Organization 98/574 standard \[[@B22]\]. Although the GHRP-2 test is not included in the Endocrine Society Guidelines \[[@B23]\], the GHRP-2 test is considered to be safe \[[@B24]\] and widely used to diagnose SGHD in Japan because of its high sensitivity and specificity compared with the insulin tolerance test \[[@B25]\]. The peak GH concentration after GHRP-2 stimulation was ≥9 ng/mL in 40 patients (SGHD^−^) and \<9 ng/mL in 32 patients (SGHD^+^). Etiologies of the SGHD^−^ patients included 11 nonfunctioning pituitary adenoma, 10 Rathke cyst, eight prolactinoma, two Cushing disease, two acromegaly, and others. Etiologies of the SGHD^+^ patients included 17 nonfunctioning pituitary adenoma, five craniopharyngioma, four Rathke cyst, and others. In all patients with hormonally functioning tumor, their remissions were confirmed. Sixteen of the SGHD^+^ patients received GH replacement therapy for an average of 8.4 months (6 to 18 months). The GH doses were titrated to maintain their insulin-like growth factor 1 (IGF-1) levels to age-adjusted IGF-1 levels unless adverse effects manifested.

B. Animals {#s8}
----------

All procedures and animal care were approved by our Institutional Animal Research Committee and conformed to the animal care Guideline for the Care and Use of Laboratory Animals of Tokyo Women's Medical University. Male C57BL/6-Ham-Slc *ob/ob* and *+/+* mice were purchased from Japan SLC (Hamamatsu, Japan). All mice were fed a normal diet, and at 10 weeks of age, 40 mg/kg pegvisomant (Pfizer, Tokyo, Japan), a GH receptor antagonist, or equivalent volume of saline was injected subcutaneously for 5 consecutive days. One day after the final injection, the mice were killed by decapitation under isoflurane inhalation anesthesia (Intervet, Tokyo, Japan). The serum, liver, kidneys, perigonadal fat as white AT (WAT), and gastrocnemius muscles were obtained. WAT weight was measured, and the obtained organs were quickly frozen in liquid N~2~ and stored at −80°C.

C. Mouse Adipocyte Experiments {#s9}
------------------------------

The 3T3-L1 mouse preadipocyte cells were obtained from the Japanese Collection of Research Bioresources \[Kyoto, Japan; JCRB9014, Research Resource Identifier (RRID): CVCL_0123\]. Cells were seeded on collagen-coated plates (Corning, Corning, NY) at 4000 cells/cm^2^, incubated for 6 days with Dulbecco's modified Eagle medium (DMEM; Life Technologies, Tokyo, Japan) with 10% bovine serum albumin (Life Technologies, Tokyo, Japan), and then incubated for 3 days in the differentiation medium: DMEM with 10% fetal bovine serum (Life Technologies, Tokyo, Japan), 0.5 mM 3-isobutyl-1-methylxanthine (Sigma-Aldrich, St. Louis, MO), 1 µM dexamethasone (Sigma-Aldrich, St. Louis, MO), and 10 µg/mL insulin (Wako, Osaka, Japan). Thereafter, maintenance medium of DMEM, including 10% fetal bovine serum and 10 µg/mL insulin, was replaced every 3 days after differentiation. The cells were used for experiments, 5 to 8 days after seeding. All medium contained 50 U/mL penicillin and 50 µg/mL streptomycin (Nacalai Tesque, Kyoto, Japan). Cells were maintained in humidified air with 5% CO~2~ at 37°C.

For small interfering RNA (siRNA) experiments, differentiated cells in maintenance medium were transfected as previously described \[[@B26]\]. In brief, cells were replated at 116,000 cells/cm^2^, and (P)RR siRNA (MSS230245:ATP6AP2 siRNA) or scrambled siRNA (Thermo Fisher Scientific, Waltham, MA) was transfected using Lipofectamine RNAiMAX Transfection Reagent (Thermo Fisher Scientific, Waltham, MA) and OptiMEM (Life Technologies, Tokyo, Japan), according to the manufacturer's protocol.

At 48 hours after transfection, the medium was replaced to serum-free maintenance medium, and cells were placed into the Hypoxic Incubator Chamber (Stemcell Technologies, Vancouver, Canada) to be incubated under an hypoxic or a normoxic condition at 37°C for 8 hours. To maintain an hypoxic condition, the chamber was filled with 5% oxygen, 5% CO~2~, and 90% nitrogen.

For Western blot, whole cell lysates were prepared using lysis buffer \[Tris-buffered saline (TBS; 25 mM Tris, 137 mM NaCl, 2.68 mM KCl), 1% Nonidet P-40, 1 mM dithiothreitol, and protease inhibitor cocktail (Nacalai Tesque, Kyoto, Japan)\]. Protein samples (10 µg) were separated by 12.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to polyvinylidene difluoride membranes (GE Healthcare, Little Chalfont, Buckinghamshire, United Kingdom). Membranes were blocked in 5% (w/v) nonfat dry milk in TBS containing 0.1% Tween 20 at room temperature for 1 hour, incubated overnight at 4°C with primary antibodies, washed in TBS containing 0.1% Tween 20, and incubated for 1 hour with appropriate secondary immunoglobulin G (IgG) horseradish peroxidase-linked antibodies. Blots were visualized using chemiluminescence reagent (Nacalai Tesque, Kyoto, Japan) and LuminoGraph I (Atto, Tokyo, Japan). Antibodies used were anti-ATP6AP2 (HPA003156, RRID: [AB_1078245](http://antibodyregistry.org/search.php?q=AB_1078245); Atlas Antibodies, Bromma, Sweden), anti-PDH E1 *β* subunit (PDHB; WH0005162M3, RRID: [AB_2236961](http://antibodyregistry.org/search.php?q=AB_2236961); Sigma-Aldrich, St. Louis, MO), anti-*β*-actin (\#4980, RRID: [AB_2223172](http://antibodyregistry.org/search.php?q=AB_2223172); Cell Signaling Technology, Danvers, MA), anti-rabbit IgG (A0545, RRID: [AB_257896](http://antibodyregistry.org/search.php?q=AB_257896); Sigma-Aldrich, St. Louis, MO), and anti-mouse IgG (NA9310, RRID: [AB_772193](http://antibodyregistry.org/search.php?q=AB_772193); GE Healthcare, Little Chalfont, Buckinghamshire, United Kingdom). Densitometry was performed using ImageJ software (NIH, Bethesda, MD).

D. Assays {#s10}
---------

Creatinine, plasma glucose, \[hemoglobin A1c (HbA1c) National Glycohemoglobin Standardization Program (NGSP)\], low-density lipoprotein (LDL)-cholesterol, high-density lipoprotein (HDL)-cholesterol, and triglyceride were measured by standard laboratory methods at our clinical laboratory center. Estimated glomerular filtrating rate (GFR) was calculated using the formula developed by the Japanese Society of Nephrology \[[@B27]\]. Serum GH concentrations of patients were measured using enzyme immunoassay (Tosoh Bioscience, Tokyo, Japan), calibrated with recombinant WHO 98/574 standard. Serum IGF-1 concentrations of patients were measured using the immunoradiometric assay "Daiichi" (Fujirebio, Tokyo, Japan). IGF-1 standard deviation (SD) score was calculated based on the age- and sex-specific normative data of IGF-1 in the Japanese population \[[@B28]\]. Serum IGF-1 concentrations of mice were measured using the insulin-like growth factor I enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems, Minneapolis, MN). Serum s(P)RR concentrations of patients and mice were measured using the Soluble (Pro)renin Receptor ELISA Assay Kit (Takara Bio, Shiga, Japan) \[[@B29]\]. Each ELISA assay was performed according to the manufacturer's protocol, and absorbance was measured by Chameleon V (Hidex, Turku, Finland) for s(P)RR and Spectra Max i3 (Molecular Devices, San Jose, CA) for IGF-1.

E. Quantitative Real-Time Polymerase Chain Reaction {#s11}
---------------------------------------------------

Total RNA was extracted from mouse tissue and cell lysate using TRIzol (Thermo Fisher Scientific, Waltham, MA). Reverse transcription was performed with total RNA using the High Capacity cDNA Reverse Transcription Kit (Life Technologies, Tokyo, Japan). Expressions of (P)RR---furin, and a disintegrin and metalloprotease (ADAM)19---mRNA were determined by quantitative real-time reverse transcriptase-polymerase chain reaction using TaqMan Gene Expression Assay (Life Technologies, Tokyo, Japan) on StepOnePlus (Life Technologies, Tokyo, Japan). Target mRNA expression was corrected by 18S ribosomal mRNA expression, shown as relative expression ratio. All samples were analyzed in duplicate.

F. Statistical Analyses {#s12}
-----------------------

All data were shown as means ± SD except for peak GH response to GHRP-2 which was expressed as median (range). Baseline characteristics of the patients were compared between SGHD^−^ and SGHD^+^ patients by unpaired *t* test, whereas levels of GH peak response to GHRP-2 were by Mann-Whitney *U* test. Categorical variables were compared using the Pearson's *χ*^2^ test. Serum s(P)RR and IGF-1 concentration and IGF-1 SD score of the patients were compared between before and after GH replacement therapy by paired *t* test. Multiple comparisons were analyzed using Tukey-Kramer test. Because of skewed distribution, levels of GH peak response to GHRP-2 were log transformed for regression analyses. In multivariate regression analysis, explanatory factors were selected from the results of univariate regression analysis. The threshold for significance was *P* \< 0.05. All statistical analyses were performed using JMP Pro 12 (SAS Institute, Tokyo, Japan).

3. Results {#s13}
==========

A. Characteristics of Patients {#s14}
------------------------------

Characteristics of the patients with (SGHD^+^) or without (SGHD^−^) GHD are shown in [Table 1](#T1){ref-type="table"}. BMI and serum levels of creatinine and triglyceride were significantly higher, and estimated GFR and serum HDL-cholesterol level were significantly lower in the SGHD^+^ patients than in the SGHD^−^ patients. Number of deficit anterior pituitary hormones and frequency of diabetes insipidus were higher in the SGHD^+^ patients than in the SGHD^−^ patients, and IGF-1, IGF-1 SD scores, and GH peak response to GHRP-2 were significantly lower in the SGHD^+^ patients than in the SGHD^−^ patients.

###### 

Baseline Characteristics of the Study

                                                  SGHD^−^ (n = 40)    SGHD^+^ (n = 32)   *P* Trend
  ----------------------------------------------- ------------------- ------------------ -----------
  Male, n (%)                                     10 (25)             14 (44)            0.094
  Age, y                                          47.0 ± 17.0         51.2 ± 18.2        0.321
  BMI, kg/m^2^                                    21.6 ± 3.4          25.7 ± 5.3         \<0.001
  Hypertension, n (%)                             12 (30)             9 (28)             0.862
  Systolic BP, mmHg                               122 ± 19            120 ± 15           0.638
  Diastolic BP, mmHg                              72 ± 13             70 ± 10            0.389
  Creatinine, mg/dL                               0.68 ± 0.18         0.82 ± 0.15        0.001
  Estimated GFR, mL/min/1.73 m^2^                 83.6 ± 17.1         69.4 ± 15.2        \<0.001
  Plasma glucose, mg/dL                           93.2 ± 10.9         98.5 ± 38.0        0.406
  HbA1c (NGSP), %                                 5.6 ± 0.5           5.9 ± 1.0          0.108
  LDL-cholesterol, mg/dL                          111.5 ± 34.2        125.7 ± 35.3       0.099
  HDL-cholesterol, mg/dL                          66.0 ± 15.9         52.7 ± 13.6        \<0.001
  Triglyceride, mg/dL                             88.6 ± 36.5         159.3 ± 69.2       \<0.001
  Number of deficit anterior pituitary hormones   0.2 ± 0.7           2.9 ± 1.1          \<0.001
  Diabetes insipidus, n (%)                       2 (5)               11 (34)            0.001
  IGF-1, ng/mL                                    137.1 ± 43.9        76.6 ± 32.7        \<0.001
  IGF-1 SD score                                  −0.5 ± 1.1          −2.4 ± 1.5         \<0.001
  GH peak response to GHRP-2, ng/mL               30.3 (9.9--114.6)   1.4 (0.03--8.56)   \<0.001

Data are shown as means ± SD except for GH peak response to GHRP-2 which is shown as median (range).

Abbreviation: BP, blood pressure.

B. Serum s(P)RR Concentration in Obese and Lean Patients With or Without SGHD {#s15}
-----------------------------------------------------------------------------

Serum s(P)RR concentration was significantly higher in the SGHD^+^ patients (23.2 ± 2.3 ng/mL) than in the SGHD^−^ patients \[21.7 ± 3.5 ng/mL; [Fig. 1(a)](#F1){ref-type="fig"}\]. When the patients were divided into four groups by obesity and SGHD, the serum s(P)RR concentration in the SGHD^+^ patients with obesity (Obese SGHD^+^; 25.2 ± 3.2 ng/mL) was significantly higher than that in the SGHD^+^ patients without obesity \[Lean SGHD^+^; 21.9 ± 2.9 ng/mL; [Fig. 1(b)](#F1){ref-type="fig"}\]. No significant effect of obesity on the serum s(P)RR concentration was observed in the SGHD^−^ patients (Obese SGHD^−^ 23.0 ± 6.2 ng/mL vs Lean SGHD^−^ 21.5 ± 3.0 ng/mL). Serum s(P)RR concentration in Lean SGHD^+^ was not significantly different from that of Lean SGHD^−^. Obese SGHD^+^ patients showed an insignificant tendency for an increased serum s(P)RR level than Obese SGHD^−^ patients. In the SGHD^+^ patients who received GH replacement therapy (average 2.3 ± 0.5 mg/week), the GH replacement therapy significantly increased their serum IGF-1 concentrations (87.6 ± 42.1 to 166.6 ± 51.8 ng/mL) and IGF-1 SD scores (−2.3 ± 1.6 to 0 ± 1.4) and decreased their serum s(P)RR concentrations \[30.3 ± 2.7 to 26.9 ± 4.6 ng/mL; [Fig. 1(c)--1(e)](#F1){ref-type="fig"}\]. There was no significant change in body weight after GH replacement (before GH: 77.6 ± 13.1 vs after GH: 78.6 ± 13.3 kg). Changes in serum s(P)RR concentration did not significantly correlate with GH dose or changes in BMI \[[Fig. 1(f)](#F1){ref-type="fig"}\].

![Effect of SGHD and obesity on serum s(P)RR concentration in humans. (a) Serum s(P)RR concentration of the patients with SGHD (SGHD^+^, n = 32) or without SGHD (SGHD^−^, n = 40). \**P* \< 0.05 vs SGHD^−^. (b, upper) BMI and (lower) serum s(P)RR concentration of the patients classified based on obesity and SGHD. \**P* \< 0.05 vs Lean SGHD^−^; †*P* \< 0.05 vs Lean SGHD^+^. (c--e) Change of serum (c) IGF-1 levels, (d) IGF-1 SD score, and (e) serum s(P)RR concentration, before and after GH replacement therapy (n = 16). \**P* \< 0.05 vs before the therapy. (f) Correlation between the changes in serum s(P)RR concentration and the changes in BMI.](js.2017-00447f1){#F1}

C. Regression Analyses of Serum s(Pro)Renin Receptor Level {#s16}
----------------------------------------------------------

Univariate regression analyses of serum s(P)RR concentration showed significant positive correlations with BMI and creatinine and negative correlations with HDL-cholesterol and natural logarithm (ln) of GH peak response to GHRP-2 ([Table 2](#T2){ref-type="table"}). BMI was the only significant explanatory variable in a multivariate regression analysis testing BMI, HDL-cholesterol, creatinine, and ln (GH peak response to GHRP-2; [Table 3](#T3){ref-type="table"}).

###### 

Univariate Regression Analysis of Serum s(P)RR Level and Baseline Characteristics and Metabolic Parameters (n = 72)

  Factors                                  r        *P* Trend
  ---------------------------------------- -------- -----------
  Age                                      −0.008   0.946
  BMI                                      0.409    \<0.001
  Creatinine                               0.328    0.005
  Estimated GFR                            −0.176   0.145
  HbA1c (NGSP)                             0.063    0.625
  LDL-cholesterol, mg/dL                   0.201    0.100
  HDL-cholesterol, mg/dL                   −0.291   0.015
  Triglyceride, mg/dL                      0.211    0.080
  IGF-1 SD score                           −0.089   0.465
  ln (GH peak response to GHRP-2, ng/mL)   −0.284   0.017

###### 

Multivariate Regression Analysis of Serum s(P)RR Level (n = 72)

  Factors                           *β* Value   *P* Trend
  --------------------------------- ----------- -----------
  BMI                               0.210       0.037
  HDL-cholesterol                   −0.016      0.560
  Creatinine                        4.023       0.105
  ln (GH peak response to GHRP-2)   −0.136      0.538

D. (P)RR in Obese and Lean Mice With or Without Growth Hormone Receptor Blockade {#s17}
--------------------------------------------------------------------------------

Five-day treatment of pegvisomant significantly decreased serum IGF-1 levels compared with treatment with saline in both lean and obese mice \[[Fig. 2(a)](#F2){ref-type="fig"}\]. The IGF-1 levels were similar between the pegvisomant-treated lean and obese mice. Blood glucose level \[[Fig. 2(b)](#F2){ref-type="fig"}\], body weight \[[Fig. 2(c)](#F2){ref-type="fig"}\], and WAT weight/body weight \[[Fig. 2(d)](#F2){ref-type="fig"}\] were significantly higher in obese mice than in lean mice but were not significantly different between the mice treated with saline and pegvisomant. The serum s(P)RR level was significantly higher in the obese mice than that in the lean mice regardless of the treatments \[[Fig. 2(e)](#F2){ref-type="fig"}\]. Pegvisomant treatment significantly increased WAT (P)RR mRNA expression only in obese mice \[[Fig. 3(a)](#F3){ref-type="fig"}\]. Expression of (P)RR mRNA in the gastrocnemius muscle, liver, or kidneys was not significantly different among the four groups. The mRNA expression of (P)RR processing enzymes, furin and ADAM19, in WAT was similar among the four groups \[[Fig. 3(b)](#F3){ref-type="fig"}\].

![Effect of GH receptor blockade and obesity on serum s(P)RR concentration in mice. Serum (a) IGF-1 concentration, (b) blood glucose concentration, (c) body weight, (d) WAT weight ratio to body weight, and (e) s(P)RR concentration in lean and obese mice treated with saline or pegvisomant (Peg). \**P* \< 0.05 vs Lean + Saline mice; †*P* \< 0.05 vs Lean + Peg mice; ‡*P* \< 0.05 vs Obese + Saline mice.](js.2017-00447f2){#F2}

![Expression of (P)RR mRNA and its processing enzyme mRNA in lean and obese mice treated with saline or pegvisomant (Peg). (a) Relative mRNA expression of (P)RR of WAT, gastrocnemius muscle, liver, and kidneys of the lean and obese mice treated with or without the pegvisomant treatment. (b) Relative mRNA expression of furin and ADAM19 of the WAT. \**P* \< 0.05 vs Lean + Saline mice; †*P* \< 0.05 vs Lean + Peg mice; ‡*P* \< 0.05 vs Obese + Saline mice.](js.2017-00447f3){#F3}

E. Effects of Hypoxia on (P)RR Expression and PDH Activity in 3T3-L1 Cells {#s18}
--------------------------------------------------------------------------

In the differentiated 3T3-L1 cells, 5% hypoxia treatment of 8 hours significantly increased (P)RR protein expression by 52% without altering (P)RR mRNA expression \[[Fig. 4(a) and 4(b)](#F4){ref-type="fig"}\]. (P)RR siRNA treatment knocked down the (P)RR mRNA expression to 10.3 ± 4.9% compared with scrambled siRNA \[[Fig. 4(c)](#F4){ref-type="fig"}\]. Hypoxia treatment did not alter PDHB expression in the cells treated with scrambled siRNA. However, hypoxia treatment significantly decreased PDHB expression in the cells treated with (P)RR siRNA \[[Fig. 4(d)](#F4){ref-type="fig"}\].

![Effects of hypoxia on (P)RR and PDHB expression in 3T3-L1 cells. (a) Representative Western blot image and protein levels for (P)RR and *β*-actin expression after normoxia or 5% hypoxia treatment of 8 hours. \**P* \< 0.05 vs normoxia. (b) Relative mRNA expression of (P)RR after normoxia or 5% hypoxia treatment of 8 hours. (c) Relative mRNA expression of (P)RR after the 48-hour treatment with scrambled or (P)RR siRNAs. \**P* \< 0.05 vs scrambled siRNA. (d) Representative Western blot image for (P)RR, PDHB, and *β*-actin after the 48-hour treatment with scrambled or (P)RR siRNAs, followed by 8-hour treatment of normoxia or 5% hypoxia.](js.2017-00447f4){#F4}

3. Discussion {#s19}
=============

In this study, we found an elevated serum s(P)RR concentration in SGHD patients, especially with obesity and elevated (P)RR expression in the WAT of obese mice with GH receptor blockade. We also showed the possibility of tissue hypoxia as an additional factor contributing to elevated (P)RR expression in the AT of GHD patients.

SGHD patients showed higher serum s(P)RR concentration than those without SGHD, and GH replacement therapy ameliorated the elevated s(P)RR concentration. Higher serum s(P)RR concentration was observed in obese SGHD patients than in lean SGHD patients, and regression analyses revealed that BMI was the only substantial explanatory variable for serum s(P)RR concentration. As AT weight is increased in GHD patients \[[@B30]\], we considered AT as a possible source of high-serum s(P)RR in obese SGHD patients.

To mimic GHD, we performed GH receptor blockade in lean and obese mice. Serum s(P)RR concentration was increased in obese mice, with and without GH receptor blockade, compared with lean mice. Whereas the mRNA expression of (P)RR was comparable in the muscle, liver, and kidneys among control and obese mice regardless of GH receptor blockade, (P)RR mRNA expression in AT after treatment with the GH receptor antagonist was significantly higher than that with saline in obese mice. The mRNA expression of (P)RR processing enzymes---furin \[[@B31]\] or ADAM19 \[[@B32]\]---was unchanged by GH receptor blockade in AT. These results suggested that increased expression, but not cleavage of (P)RR in AT, may be the cause of elevated serum s(P)RR concentration in GHD patients.

Hypoxia in ATs of obese model animals has been reported \[[@B16]\]. GHD also can cause hypoxia in AT. Patients with GHD have impaired aerobic exercise capacity, as decreased cardiac function \[[@B33]\], lung volume \[[@B34], [@B35]\], and red cell mass \[[@B6]\] reduce oxygen delivery to muscles. These suggest that AT of obese patients with GHD may also be hypoxic. Previous studies showed that hypoxia stimulates PDH kinase (PDK) expression \[[@B36], [@B37]\]. Generally, hypoxia increases PDK activity and decreases PDH activity. As illustrated in [Fig. 5](#F5){ref-type="fig"}, a recent study showed that (P)RR is capable of maintaining PDH activity through stabilizing a PDHB protein \[[@B12]\]. In the current study, knockdown of (P)RR decreased expression of PDHB only in the hypoxic condition. These data suggest that the hypoxic condition in AT may be a contributing factor for elevated s(P)RR in obese GHD patients.

![Hypothetic regulation of PDH activity by (P)RR in ATs. Under hypoxic condition and GHD, PDH activity tends to decrease through the hypoxia-induced stimulation of PDK. However, hypoxia also enhances the (P)RR expression. As (P)RR binds to PDHB and thus maintains the PDH activity, PDH activity is actually unchanged even under hypoxic conditions if the expression of (P)RR is intact. CoA, coenzyme A; TCA, tricarboxylic acid.](js.2017-00447f5){#F5}

Potential clinical implications from this study may be illustrated as follows. First, the tissue renin-angiotensin system may be activated in AT in GHD patients. It has been shown that hypertensive patients have elevated serum s(P)RR, likely as a result of the activated intrarenal renin-angiotensin system \[[@B13]\]. In GHD patients, the prorenin-to-renin ratio was found to be increased \[[@B38]\], and we observed elevated (P)RR expression in the WAT of GHD model mice. As circulating prorenin can bind to (P)RR and acquire enzymatic activity without proteolytic cleavage \[[@B9]\], increased (P)RR in AT and prorenin in blood may synergistically activate the tissue renin-angiotensin system in AT in GHD patients. Second, (P)RR may contribute to the maintenance of PDH activity in adipocytes. The elevation of serum s(P)RR concentration in GHD patients was likely a result of the increased (P)RR expression in AT. As (P)RR binding to PDH protein blocks phosphorylation and degradation of PDH, increased expression of (P)RR may preserve efficient energy metabolism but may also lead to increased oxidative stress in obesity and GHD, the effects of which remain to be determined.

This study has several limitations. First, it is unclear whether elevated serum s(P)RR concentration in GHD patients is a result of an increase in the volume of ATs or (P)RR expression in ATs. The changes in serum s(P)RR concentration did not correlate with changes in BMI after GH replacement, but the current study did not examine (P)RR expression in ATs in the patients. Second, the mechanism for the increased expression of (P)RR with hypoxia remains to be determined. Hypoxia induces glycolysis \[[@B39]\], adipogenesis \[[@B40]\], and adipokine production \[[@B41]\]. Whether these metabolic pathways affect the (P)RR expression in AT should be examined in future studies. Third, SGHD was diagnosed by a single test, the GHRP-2 test, in the current study. As GH cutoff values for mild to moderate GHD have not been determined for the GHRP-2 test, SGHD^−^ patients in the current study include those with mild to moderate GHD. Whether serum s(P)RR concentration in the patients with mild to moderate GHD are increased compared with those without GHD cannot be determined from this study.

In conclusion, the current study showed that serum s(P)RR concentrations were elevated in obese patients with GHD. The origin of the elevated serum s(P)RR concentration was suggested to be the AT from the animal studies, and *in vitro* studies suggested that hypoxia may be one of the causes of elevated (P)RR expression in AT. The increased expression of (P)RR may contribute to the maintenance of energy metabolism in AT. Thus, the elevated serum s(P)RR levels may reflect hypoxic ATs caused by GHD and obesity. Further studies are needed to clarify the regulation of (P)RR expression under hypoxic conditions.

In this research, we used instruments of the Medical Research Institute (MRI) of Tokyo Women's Medical University.
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